Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q5ST30
UPID:
SYVM_HUMAN
Alternative names:
Valyl-tRNA synthetase; Valyl-tRNA synthetase-like
Alternative UPACC:
Q5ST30; A2ABL7; B4DET4; B4E3P5; F5GXJ0; F5H323; Q2M2A0; Q59FI1; Q5SQ96; Q5SS98; Q6DKJ5; Q6ZV24; Q96GN2; Q96H77; Q96Q02; Q9H6R2; Q9UFH7
Background:
Valine--tRNA ligase, mitochondrial, also known as Valyl-tRNA synthetase, plays a crucial role in protein synthesis by attaching valine to its corresponding tRNA. This enzyme is essential for mitochondrial function and energy production.
Therapeutic significance:
Linked to Combined oxidative phosphorylation deficiency 20, a disorder characterized by muscle weakness, neurological disease, and cardiomyopathy, understanding Valine--tRNA ligase's role could unveil new therapeutic strategies.